Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
opioid |
| gptkbp:approvedBy |
gptkb:FDA
2021 |
| gptkbp:ATCCode |
N07AX32
|
| gptkbp:brand |
gptkb:Lybalvi
|
| gptkbp:CASNumber |
197855-65-5
|
| gptkbp:chemicalFormula |
C21H26N2O4
|
| gptkbp:combines |
gptkb:olanzapine
|
| gptkbp:developedBy |
gptkb:Alkermes
|
| https://www.w3.org/2000/01/rdf-schema#label |
samidorphan
|
| gptkbp:indication |
treatment of schizophrenia
treatment of bipolar I disorder |
| gptkbp:IUPACName |
17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
|
| gptkbp:legalStatus |
prescription only (Rx-only)
|
| gptkbp:mechanismOfAction |
mu-opioid receptor antagonist
partial agonist at kappa- and delta-opioid receptors |
| gptkbp:molecularWeight |
370.44 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
ALKS-33
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:Lybalvi
|
| gptkbp:bfsLayer |
8
|